Abstract
The Dutch company Micreos has raised about $34 million to further develop enzyme-based antibiotics called endolysins. The enzymes are normally made by bacteriophages, viruses that selectively kill specific strains of bacteria. The company already offers a nonprescription skin-care product called Gladskin containing endolysins that specifically kill the bacteria Staphylococcus aureus to treat conditions such as acne and eczema. Micreos plans to begin selling Gladskin in the US this year.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
